The therapeutic potential of PDE4 inhibitors

Bibliography

• KREBS EG, BEAVO JA: Phosphorylation-dephosphorylation of enzymes. Ann. Rev. Biochem. (1979) 48:923–959.
   PubMed Web of Science ®Google Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75:725–748.
   PubMed Web of Science ®Google Scholar
• CONTI M, NEMOZ G, SETTE C, VICINI E: Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr. Rev. (1995) 16:370–389.
   PubMed Web of Science ®Google Scholar
• MANGANIELLO VC, MURATA T, TAIRA M, BELFRAGE P, DEGERMAN E: Diversity in cyclic nucleotide isoenzyme families. Arch. Biochem. Biophys. (1995) 322:1–13.
   PubMed Web of Science ®Google Scholar
• FISCHER DA, SMITH JF, PILLAR JS, ST DENIS SH, CHENG JB: Isolation and characterisation of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. (1998) 246:570–577.
   PubMed Web of Science ®Google Scholar
• SODERLING SH, BAYUGA SJ, BEAVO JA: Cloning and characterisation of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. NMI Acad. Sci. (1998) 95:8991–8996.
   PubMed Web of Science ®Google Scholar
• FISCHER DA, SMITH JF, PILLAR JS, ST DENIS SH, CHENG JB: Isolation and characterisation of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. (1998) 273(25):15559–15564.
   PubMed Web of Science ®Google Scholar
• FUJISHIGE K, KOTERA J, MICHIBATA H et al.: Cloning and characterisation of a novel human phosphodies-terase that hydrolyses both cAMP and cGMP (PDE10A). J. Biol. Chem. (1999) 274:18438–18445.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents. Am. J. Respir. Grit. Care Med. (1998) 157:351–370.
   Google Scholar
• ••An excellent review.
   Google Scholar
• BARNES PJ: Molecular mechanisms of antiasthma therapy. Ann. Med. (1995) 27:531–535.
   PubMed Web of Science ®Google Scholar
• DRAZEN JM, ARM, JP, AUSTEN KF: Sorting out the cytokines of asthma. J. Exp. Med. (1996) 183:1–5.
   PubMed Web of Science ®Google Scholar
• PALMA CARLOS AG, PALMA CARLOS ML, CONCEICAO SM, ALCINDA M: Cytokines and asthma. J. Invest. Allergol Immunol. (1997) 7:270–273.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST: The inflammatory basis of asthma and its implications for drug treatment. Clin. Ex. Allergy (1996) 26:1–4.
   PubMed Web of Science ®Google Scholar
• AZZAWI M, BRADLEY B, JEFFERY PK et al.: Identification of activated T lymphocytes and eosinophils in bronchial biopsies in sTable atopic asthma. Am. Rev. Respir. Dis. (1990) 142:1407–1413.
   PubMed Web of Science ®Google Scholar
• JAIN P, GOLISH JA: Clinical management of asthma in the 1990s. Drugs (1996) 52 :1–11.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Immunomodulation as asthma therapy: where do we stand? Eur. Respir. J. (1996) 9\(Suppl. 22):154s–159s.
   Google Scholar
• VIANNA EO, MARTIN RJ: Recent innovations in asthma therapy. Drugs Tod. (1998) 34(4):341–351.
   PubMed Web of Science ®Google Scholar
• •A useful review.
   Google Scholar
• PAUWELS RA, JOOS GF, KIPS JC: Leukotrienes as therapeutic target in asthma. Allergy (1995) 50:615–622.
   PubMed Web of Science ®Google Scholar
• SPINA D, LANDELLS LJ, PAGE CP: The role of theophyl-line and phosphodiesterase4 isozyme inhibitors as anti-inflammatory drugs. Clin. Ex. Allergy (1998) 28\(Suppl. 3):24–34.
   Google Scholar
• RABE KF, MAGNUSSEN H, DENT G: Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur. Respir. J. (1995) 8:637–642.
   PubMed Web of Science ®Google Scholar
• COWARD WR, SAGARA H, CHURCH MK: Asthma, adenosine, mast cells and theophylline. Clin. Ex. Allergy (1998) 28\(Suppl. 3):42–46.
   Google Scholar
• RABE KF, DENT G: Theophylline and airway inflamma-tion. Clin. Ex. Allergy (1998) 28\(Suppl. 3):35–41.
   Google Scholar
• CHURCH MK, FEATHERSTONE RL, CUSHLEY MJ, MANN JS, HOLGATE ST: Relationships between adenosine, cyclic nucleotides and xanthines in asthma. J. Allergy Clin. Immunol. (1986) 78:670–675.
   PubMed Web of Science ®Google Scholar
• HOWELL RE, MUEHSAM WT, KINNIER WJ: Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci. (1990) 46:563–568.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, UNDEM BJ, CIESLINSKI LB, LUTTMAN MA, REEVES MK, HAY DWP: Identification, characterisation and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. (1993) 265:1213–1223.
   PubMed Web of Science ®Google Scholar
• DE BOER J, PHILPOTT AJ, VAN AMSTERDAM RG, SHAHID M, ZAAGSMA J, NICHOLSON CD: Human broncial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. (19 9 2) 106:1028-1034.
   Google Scholar
• CROSSLAND J: Rolipram. Drugs Future (1988) 13 (1):38–41.
   Google Scholar
• CROSSLAND J: Rolipram. Drugs Future (1998) 23 (1) :108–109.
   Google Scholar
• SHEPPARD H, WIGGAN G: Analogues of 4-(3,4-dimethoxybenzy0-2-imidazolidinone as potent inhibitors of rat erythrocyte adenosine cyclic 3',5'-phosphate phosphodiesterase. Mol. Pharmacol. (1971) 7:111–115.
   PubMed Web of Science ®Google Scholar
• TURNER CR, COHAN VL, CHENG JB, SHOWELL HJ, PAZOLES CJ, WATSON JW: The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J. Pharmacol. Exp. Ther. (1996) 278: 1349–1355.
   PubMed Web of Science ®Google Scholar
• •Useful reference describing Pfizer's compound.
   Google Scholar
• WRIGHT KF, TURNER CR, JAYASINGHE-BECK R, COHENVL, CHENG JB, WATSON JW: Differential in vivo and in vitro bronchorelaxant activities of CP-80633, a selective phosphodiesterase 4 inhibitor. Can. J. Physic)]. Pharmacol. (1997) 75:1001–1008.
   PubMed Web of Science ®Google Scholar
• WATSON JW, BECK R, COHAN VL, SHOWELL HJ, PAZOLESCJ, CHENG JB: Antianaphylactic and side effect activity of the PDEIV inhibitor CP-80,633 in the ferret. J. Allergy Immunol. (1995) 95:353.
   Web of Science ®Google Scholar
• DUPLANTIER AJ, ANDRESEN CJ, CHENG JB et al.:7-0xo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of human eosinophil phosphodi-esterase. J. Med. Chem. (1998) 41:2268–2277.
   PubMed Web of Science ®Google Scholar
• DUPLANTIER AJ, ANDRESEN CJ, CHENG JB et al.: 7-0xo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridines as novel inhibitors of phosphodiesterase 4. Fifth Chemical Congress of N America (1997). Abstract 02/897.
   Google Scholar
• HUGHES B, HOLBROOK M, ALLEN R et al.: Suppression of antigen-induced airway responses and bronchial hyperresponsiveness by CDP840, a novel stereo-selective inhibitor of phosphodiesterase Type IV. Br. J. Pharmacol. (1995) 116:(Proc. Suppl.) Abstract 6P.
   Google Scholar
• LISLE H, HUGHES B, HOWAT D: The effect of CDP840 ineosinophil and neutrophil models of inflammation: Inflamm. Res. (1995) 44\(suppl. 3):W02/17.
   Google Scholar
• HOLBROOK M, KINGABY R, BLEASE K, HUGHES B, HIGGS G: Anti-inflammatory effects of CDP840, a novel potent and selective phosphodiesterase (PDE) Type IV inhibitor. Inflamm. Res. (1995) 44\(Suppl. 3):W12/12.
   Google Scholar
• •Useful reference describing Celltech's compound.
   Google Scholar
• HOLBROOK M, GOZZARD N, JAMES T, HIGGS G, HUGHES B: Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase Type 4 inhibitor. Br. J. Pharmacol (1996) 118:1192–1200.
   PubMed Web of Science ®Google Scholar
• HOLBROOK M, GOZZARD N, HUGHES B: CDP840 inhibits ozone (03)-induced airway hyper-responsiveness (AHR) to inhaled histamine in anaesthetised guinea-pigs. Inflamm. Res. (1995) 44\(Suppl. 3):W12/07.
   Google Scholar
• HUGHES B, HOWAT D, LISLE M et al.: The inhibition ofantigen-induced eosinophilia and bronchoconstric-tion by CDP840, a novel stereo-selective inhibitor of phosphodiesterase Type 4. Br. J. Pharmacol (1996) 118:1183–1191.
   PubMed Web of Science ®Google Scholar
• LISLE H, HOWAT D: Investigation of the in vivoanti-inflammatory properties of the novel and selective PDE4 inhibitor CDP840. Int. Congr. Inflamm. Res. Assoc. (1996): Abract 109.
   Google Scholar
• GOZZARD N, EL-HASHIM A, HERD CM et al.: Effect of theglucocorticosteroid budesonide and a novel phosphodiesterase Type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits. Br. J. Pharmacol. (1 9 9 6) 118:1201-1208.
   Google Scholar
• JONES TR, McAULIFFE M, McFARLANE CS, PIECHUTA H,MACDONALD D, RODGER IW: Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can. J. Physiol. Pharmacol. (1998) 76:21–217.
   Google Scholar
• RAEBURN D, UNDERWOOD SL, LEWIS SA et al.: Anti-inflammatory and bronchodilator properties of RP73401, a novel and selective phosphodiesterase Type IV inhibitor. Br.J. Pharmacol (1994) 113:1423–1431.
   PubMed Web of Science ®Google Scholar
• •Useful reference describing RPR's compound.
   Google Scholar
• BANNER KH: The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways. Pulm. Pharmacol. (1995) 8:37–42.
   PubMedGoogle Scholar
• •Good review.
   Google Scholar
• KARLSSON J-A, SOUNESS J, WEBBER S, POLLOCK K, RAEBURN D: Anti-inflammatory effects of the novel phosphodiesterase IV inhibitor RP73401. Int. Arch. Allergy Immunol. (1995) 107:425–426.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, BOCHNOWICZ S, OSBORN RR et al.:Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor 5B207499 (Ariflo) in the guinea pig. J. Pharmacol. Exp. Ther. (1998) 287(3):988–995.
   PubMed Web of Science ®Google Scholar
• •Useful reference describing SB's compound.
   Google Scholar
• UNDERWOOD DC, BOCHNOWICZ S, OSBORN R et al.: Anti-asthmatic potential of the second generation phosphodiesterase 4 inhibitor, SB 207499. Eur. Resp. J. (1997) 10\(Supp1.25):3135.
   Google Scholar
• CHRISTENSEN SB, GUIDER A, FORSTER CJ et al.: 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J. Med. Chem. (1998) 41:821–835.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S, HAYDWP, TORPHY TJ: The therapeutic activity of SB 207499 (Ariflo'), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. Amer. J. Respir. Crit. Care Med. (1998) 157:A827.
   PubMedGoogle Scholar
• KAMINUMA O, KIKKAWA H, MATSUBARA S, IKEZAWA K Inhibitory effect of a novel phosphodiesterase IV inhibitor, T-440, on antigen- and chemical mediator- induced bronchoconstrictions in guinea pigs in vivo. Jpn. Pharmacol. (1996) 72:1–8.
   PubMedGoogle Scholar
• T-440. Drugs of the future (1997) 22:729–732.
   Google Scholar
• •Good review of Tanabe Seiyaku's compound.
   Google Scholar
• KAMINUMA O, KIKKAWA H, MATSUBARA S, IKEZAWA K:Effect of T-440, a novel Type IV phosphodiesterase inhibitor, on allergen-induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs. Int. Arch. Allergy Immunol. (1997) 112:406–411.
   PubMed Web of Science ®Google Scholar
• MATSUBARA S, FUSHIMI K, KAMINURA O et al.: Effect ofT-440, a Type IV phosphodiesterase inhibitor on ozone-induced airway hyperresponsiveness and airway epithelial injury in guinea pigs. Jpn. J. Pharmacol. (1996) 71 (Suppl. 1):197P.
   Google Scholar
• MATSUBARA S, FUSHIMI K, KAMINURA O, KIKKAWA H,IKEZAWA K, NAITO K: Prevention of ozone-induced airway hyperresponsiveness and epithelial injury by phosphodiesterase inhibitors in guinea pigs. Environ. Toxicol Pharmacol. (1997) 3:201–209.
   PubMed Web of Science ®Google Scholar
• YAMAGATA S, WADA K, SUGAYA T et al.: Bronchialanti-spasmogenic effects and selectivity of T-440, phosphodiesterase Type 4 inhibitor, in the dog. Biol. Pharm. Bull. (1997) 20(12):1261–1265.
   PubMed Web of Science ®Google Scholar
• MATSUBARA S, KAMINURA O, KIKKAWA H, IKEZAWA K, NAITO K: Effects of PDE IV inhibitors on antigen-induced bronchoconstriction in rats. Comparision with guinea pigs. 70th Annual Meeting of the Japanese Pharm. Soc. (1997):P–550.
   Google Scholar
• FUJIMURA M, KITA T, MYOU S, TACHIBANA H, MATSUDA T: Bronchoprotective effects of KF-19514 and cilostazol in guinea pigs in vivo. Eur. J. Pharmacol. (1997) 327:57–63.
   PubMed Web of Science ®Google Scholar
• MANABE H, AKUTA K, SEJIMO H et al.: Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor. Eur.J. Pharmacol. (1997) 332:97–107.
   PubMed Web of Science ®Google Scholar
• MANABE H, AKUTA K, OKAMURA K, OHMORI K: KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits PAF-induced lung inflammatory responses by inhaled administration in guinea pigs. Int. Arch. Allergy Immunol. (1997) 114:389–399.
   PubMed Web of Science ®Google Scholar
• HEASLIP RJ, LOMBARDO LI GOLANKIEWICZ JM et al.: Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J. Pharmacol. Exp. Ther. (1994) 268(2):888–896.
   Google Scholar
• HEASLIP RJ, EVANS DY, SICKELS BD: Pulmonary selectivity of WAY-PDA-641 and reference PDE-IV inhibitors in the dog. FASEB J (1994) 8:371.
   PubMed Web of Science ®Google Scholar
• HOWELL RE, WOEPPEL SL, HOWELL DE etal.: Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Inflamm. Res. (1995) 44 (Suppl. 2):S172–S173.
   Google Scholar
• SUZUKI F, KURODA T, KAWAKITA T et al.: New broncho-dilators. 3. Imidazo[4,5-c][1,8]naphthyridin-4(511)-ones. J. Med. Chem. (1992) 35:4866–4874.
   Google Scholar
• MATSUURA A, ASHIZAWA N, ASAKURA R et al.: Substi-tuted 1,8-naphthyridin-2(111)-ones as selective phosphodiesterase IV inhibitors. Biol. Pharm. (1994) 17(4):498–503.
   PubMed Web of Science ®Google Scholar
• MANABE H, KURODA T, OHNO T et al.: Pharmacologicalproperties of a new bronchodilator, KF17625. Jpn. J. Pharmacol (1992) 58 (Suppl. 1):238P.
   Google Scholar
• CAVALLA D, GALE DD, SPINA D et al.: Activity ofV11294A, a novel phosphodiesterase 4 (PDE4) inhibitor, in cellular and animal models of asthma. Amer. J. Respir. Grit. Care Med. (1997) 155:A660.
   Google Scholar
• TAKAYAMA K, IWATA M, OKAMOTO Y, AOKI M, NIWA A,ISOMURA Y: Synthetic studies on selective Type IV phosphodiesterase (PDE IV) inhibitors. 214th ACS Nat. Meeting (1997) MEDI–245.
   Google Scholar
• BELETA BJ: Characterisation of LA531025: a newselective PDE IV inhibitor for bronchial asthma. Third Int. Conf on Cyclic Nucleotide Phosphodiesterases: From Genes to Therapies. Glasgow, UK (1996): Abstract 73.
   Google Scholar
• GOZZARD N, HUGHES B, WARRELLOW G, HIGGS G: Pharmacological characterisation of the neonatally sensitized rabbit model and effects of a novel phosphodiesterase (PDE) 4 inhibitor. J. Pharm. Pharmacol. (1998) 50(Suppl.):69.
   Google Scholar
• •Interesting paper detailing rabbit model.
   Google Scholar
• ESCOTT KJ, MCMILLAN SJ, BIRRELL M et al.: Pharma-cological profiling of phosphodiesterase 4 (PDE4) inhibitors and analysis of the therapeutic ratio in rats and dogs. Br. J. Pharmacol. (1998) 123 (Proc. Suppl.):40P.
   Google Scholar
• THURAIRATNAM S, ALDOUS D, BOWER S, ESCOTT KJ, GEIGER LE, IQBAL S: Biological activity and side effect profile of RPR-132294 and RPR-132703 - novel PDE4 inhibitors. XVth EFMC Int. Symp. Med. Chem. (1998).
   Google Scholar
• MARX D, POPPE H, SZELENYI I: The in vivo activity ofAWD 12-281, a potent PDE4 inhibitor for the treatment of allergic asthma. J. Allergy Clin. Immunol (1999) 103:S127.
   Web of Science ®Google Scholar
• POPPE H, KUSTERS S, SZELENYI I: Effect of AWD 12-281,a new selective PDE4-inhibitor, loteprednol and beclomethasone in models of allergic rhinitis and airway inflammation in brown norway-rats. Am. J. Respir. Crit. Care Med. (1999) A95.
   Google Scholar
• HOFGEN N, EGERLAND U, POPPE H et al.: Structurebased drug design of a new type of selective PDE4 inhibitors. XVth EFMC Int. Symp. Med. Chem. (1998):Absract P98.
   Google Scholar
• HOFGEN N, POLYMEROPOULOS E, EGERLAND U et al.:AWD 12–281, a new PDE4 inhibitor - created by ligand based drug design. 4th World Congress on Inflammation, Paris (1999):P–06–5.
   Google Scholar
• POPPE H, SZELENYI I: Effect of the new selectivePDE4-inhibitor AWD 12–281 and RPR 73401 on LPS-induced neutrophilia in ferret lung and emetogenic effects in concious ferrets. Arch. Pharmacol. (1999) 359(3):114. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(9)
   Google Scholar
• BURNOUF C, PASCAL Y, ANDRIANJARA R et al.: Pharma-cology of the novel phosphodiesterase Type 4 inhibitor CI-1018. 215thACSDallas, USA (1998) MEDI 8.
   Google Scholar
• PASCAL Y, ANDRIANJARA R, AUCLAIR et al.: Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]cliazepino [6,7,1-hi] indolines: novel PDE4 inhibitors. 215th ACSDallas, USA (1998) MEDI 50.
   Google Scholar
• SZELENYI SK, POPPE H, DENT G, MAGNUSSEN H, RABE KF: Effects of selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulmonary Pharmacol Ther. (1998) 11:13–21.
   PubMed Web of Science ®Google Scholar
• MARX D, ROLLING H, SZELENYI I: Inhibition of allergen induced bronchial hyperactivity (BHR) in BP-2 mice by cyclosporine A, fluticosone and selective PDE4 inhibitors. J. Allergy Clin. Immunol (1998) 101:S10.
   Web of Science ®Google Scholar
• MARX D, EGERLAND U, HARTUNG T, SAUCER A, SZELENYI I, WENDEL A: D-22888 - a new PDE4 inhibitor for the treatment of allergic rhinitis and other allergic disorders. J. Allergy Clin. Immunol. (1997) 99:S444.
   Google Scholar
• BURNOUF C, PASCAL Y, ANDRIANJARA R, AUCLAIR E, AVENEL N, BERTIN B: Pharmacology of the novel phosphodiesterase Type 4 inhibitor, CI-1018. 215th ACS Nat. Meeting (1998):MEDI 008.
   Google Scholar
• PRUNIAUX M-P, ROCHER M-N: The novel phosphodies-terase inhibitor CI-1018 inhibits antigen-induced lung eosinophilia in sensitised brown-norway rats -comparision with rolipram. Inflammation (1999):S–04–6.
   Google Scholar
• STIERNET F, DE LAVELEYE F, DANHAIVE P, PECK MJ, CHATELAIN P, MASSINGHAM R: UCB29936, a selective phosphodiesterase Type IV inhibitor, suppressed Sephadex-induced bronchial hyperresponsiveness to seratonin in the rat. A TS (1999):B75.
   Google Scholar
• MONTANA J, COOPER N, HUNT H et al.: Activity of D4418, a novel phosphodiesterase 4 (PDE4) inhibitor, effects in cellular and animal models of asthma and early clinical studies. Am. J. Respir. Grit. Care Med. (1999):A624.
   Google Scholar
• CHENG JB, COOPER K, DUPLANTIER AJ et al.: Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase Type IV inhibitors with greatly attenuated affinity for the [311]rolipram binding site. Bioorg. Merl. Chem. Lett. (1995) 5:1969–1972.
   Google Scholar
• IWASAKI T, KONDO K, KURODA T et al.: Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,2-bis(hydroxymethyfinaphthalene lignans. J. Merl. Chem. (1996) 39:2696–2704.
   Google Scholar
• DUPLANTIER AJ, BIGGERS MS, CHAMBERS RJ et al.: Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase Type IV versus [311]rolipram binding activity and their relationship to emetic behaviour in the ferret. J. Merl. Chem. (1996) 39:120–125.
   PubMed Web of Science ®Google Scholar
• BACHER E, BOER C, BRAY-FRENCH K et al. N-Arylrolipram derivatives as potent and selective PDE4 inhibitors. Bioorg. Merl. Chem. Lett. (1998) 8:3229–3234.
   PubMed Web of Science ®Google Scholar
• UKITA T, SUGAHARA M, TERAKAWA Y et al.: Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene deriva-tives. J. Med. Chem. (1999) 42:1088–1099.
   PubMed Web of Science ®Google Scholar
• ZELLER E, STIEF HJ, PFLUG B, SASTRE Y, HERNANDEZ M:Results of a Phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry (1984) 17:188–190.
   PubMed Web of Science ®Google Scholar
• HOROWSKI R, SASTRE-Y-HERNANDEZ M: Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Ther. Res. (1985) 38:23–29.
   Web of Science ®Google Scholar
• HEBENSTREIT GF, FELLERER K, FICHTE K et al.: Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsy-chiaby (1989) 22:156–160.
   PubMed Web of Science ®Google Scholar
• PUURUNEN J, LUCKE C, SCHWABE U: Effect of the phosphodiesterase inhibitor 4-[3-(cyclopenty-loxy)-4-methoxypheny1]-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Arch. Pharmacol. (1978) 304:69–75.
   Google Scholar
• ECKMANN F, FICHTE K, MEYA U, SASTRE-Y-HERNANEZ M: Rolipram in major depression: results of a double-blind comparative study with amitriptyline. Curr. Ther. Res. (1988) 43:291–295.
   Web of Science ®Google Scholar
• WACHTEL H: Potential antidepressant activity of rolipram and other selective cyclic adenosine 3, 5-monophosphate phosphodiesterase inhibitors. Neurpharmacology (1983) 22:267–272.
   PubMed Web of Science ®Google Scholar
• BOBON D, BREULET M, GERARD-VANDENHOVE M-A: Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur. Arch. Psychiatr. Neurol. Sci. (1988) 238:2–6.
   PubMedGoogle Scholar
• SOUNESS JE, RAEBURN D, KARLSSON J-A: Phosphodies-terase Type 4 inhibitors as potential anti-asthma agents. In: Progress in Basic and Clinical Pharmacology (Anti-asthmatic Drugs) Pauwels R, Advenier C, O'Bryne P (Eds.) Karger, Basle, Germany. (In Press).
   Google Scholar
• NICHOLSON CD: Cyclic nucleotide phosphodiesterase isoenzymes and asthma - outstanding issues. Agents Actions Suppl (1993) 43:3–12.
   PubMedGoogle Scholar
• TORPHY TJ, STADEL JM, BURMAN M et al.: Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. (1992) 267:1798–1804.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, DEWOLF WE, GREEN DW, LIVI GP: Biochemical characteristics and cellular regulation of phosphodiesterase IV. Agents Actions Suppl. (1993) 43:51–71.
   PubMedGoogle Scholar
• MULLER T, ENGELS P, FOZARD JR: Subtypes of the Type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. TIPS (1996) 17:294–298.
   PubMed Web of Science ®Google Scholar
• JACOBITZ S, MCLAUGHLIN MM, LIVI GP, BURMAN M, TORPHY TJ: Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. (1996) 50:891–899.
   PubMed Web of Science ®Google Scholar
• ROCQUE WJ, HOLMES WD, PATEL IR et al.: Detailed characterisation of a purified Type 4 phosphodies-terase, HSPDE4B2B:differentiation of high- and low-affinity (R)-rolipram binding. Protein Express. Purification (1997) 9:191–202.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, RAO S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodies-terases. Cell. Signal. (1997) 9(3/4):227–236.
   Google Scholar
• •Interesting paper discussing the high and low affinity binding sites.
   Google Scholar
• HUGHES B, OWENS R, PERRY M, WARRELLOW G, ALLEN R: PDE-4 inhibitors: the use of molecular-cloning in the design and development of novel drugs. Drug Discov. Today (1997) 2:89–101.
   Web of Science ®Google Scholar
• •Good review.
   Google Scholar
• BARNETTE MS, CHRISTENSEN SB, UNDERWOOD DC, TORPHY TJ: Phosphodiesterase 4: biological underpin-nings for the design of improved inhibitors. Pharmacol. Rev. Commun. (1997) 8:65–73.
   Google Scholar
• •Good review.
   Google Scholar
• SCHMIECHEN R, SCHNEIDER HH, WACHTEL H: Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology (1990) 102:17–20.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, GROUS M, CIESLINSKI LB, BURMAN M, CHRISTENSEN SB, TORPHY TJ: Inhibitors of phosphodi-esterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands:correlation between function and interaction with a high affinity rolipram binding site. J. Pharmacol. Exp. Ther. (1995) 273:1396–1402.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, MANNING CD, CIESLINSKI M, BURMAN M, CHRISTENSEN SB, TORPHY TJ: The ability of phosphodi-esterase IV inhibitors to suppress superoxide produc-tion in guinea-pigs is correlated with inhibition of PDE IV catalytic activity. J. Pharmacol. Exp. Ther. (1995) 273:674–679.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, GRIFFIN M, MASLEN C et al.: Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF-a generation from human monocytes by interacting with a low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol (1996) 118:649–658.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, O'LEARY BARTUS J, BURMAN M et al: Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [ [3]Hirolipram binding. Biochem. Pharmacol (1996) 51:949–956.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, HOUGHTON C, SARDAR N, WITHNALL MT: Evidence that cyclic AMP phosphodiesterase inhibi-tors suppress interleukin-2 release from murine splenocytes by interacting with a low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol (1997) 121:743–750.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, NOVAK LB et al.: Inhibi-tion of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. (1993) 266:306–313.
   PubMed Web of Science ®Google Scholar
• DUPLANTIER AJ, TURNER CR: Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes. Drug Discov. Tod. (1996) 1(5):199–208.
   Web of Science ®Google Scholar
• •Useful review.
   Google Scholar
• BRUNNEE T, ENGELSTATTER R, STEINIJANS VW, KUNKEL G : Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur. Respir. J. (1992) 5:982–985.
   PubMed Web of Science ®Google Scholar
• NORMAN P: PDE4 inhibitors 1998. Exp. Opin. Ther. Patents (1998) 8(7):771–784.
   Web of Science ®Google Scholar
• ••Excellent review.
   Google Scholar
• BURNOUF C, PRUNIAUX M-P, SZILAGYI CM: Phosphodi-esterase 4 inhibitors. Ann. Reports. Med. Chem. (1998) 33:91–109.
   Google Scholar
• ••Good review.
   Google Scholar
• LAS-31025. Clin. Trials Monitor (1997) 69:25-26. Good review.
   Google Scholar
• NORMAN P: Arofylline. Curr. Opin. Anti-inflamm. Immunomodulatoly Invest. Drugs (1999) 1:48–50.
   Google Scholar
• ••Very useful review of Almirall's compound.
   Google Scholar
• MURDOCH RD, COWLEY H, UPWARD J, WEBBER D, WYLD P: The safety and tolerability of Ariflo (SB207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers. Am. J. Respir. Grit. Care Med. (1998) 157:A409.
   Google Scholar
• NIEMAN RB, FISHER BD, AMIT O, DOCKHORN RJ: SB207499 (ARIFLO), a second generation, selective oral phosphodiesterase Type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction. Am. J. Respir. Crit. Care Med. (1998) 157:A413.
   Google Scholar
• COMPTON CH, CEDAR E, NIEMAN RB, AMIT O, LANGLEY SJ, SAPENE M: Ariflo improves lung function in patients with asthma: results of a study in patients taking inhaled corticosteroids. ALA/ATS (1999).
   Google Scholar
• MURDOCH R, COLWEY H, WEBBER D, TAYLOR A: The addition of SB 207499 (Ariflo), a novel and selective PDE4 inhibitor, to oral prednisolone, is safe and well tolerated. Eur. Res. J. (1998) 12 (Suppl. 28):362s.
   Google Scholar
• KELLY J, MURDOCH D, COWLEY H, WEBBER D, TAYLOR AC: The co-administration of SB 207499 (Ariflo), an orally active, novel and selective PDE4 inhibitor, with oral theophylline does not produce adverse drug interactions in healthy male volunteers. Eur. Res. J. (1998) 12 (Suppl. 28):362s.
   Google Scholar
• KELLY J, MURDOCH D, COWLEY H, WEBBER D: SB 207499 (Ariflo), an orally active, novel second genera-tion PDE4 inhibitor, does not potentiate the cardiovas-cular effects of nebulised salbutamol when co-administered in healthy male volunteers. Eur. Res. J. (1998) 12 (Suppl. 28):362s.
   Google Scholar
• BROWN WM: SB-207499. Curr. Opin. Anti-inflamm. Immunomodulatoiy Invest. Drugs (1999) 1:39–47.
   Google Scholar
• ••Excellent review of SB's compound.
   Google Scholar
• HARBINSON PL, MACLEOD D, HAWKSWORTH R et al.: The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur. Respir. J. (1997) 10:1008–1014.
   PubMed Web of Science ®Google Scholar
• •One of the few papers describing results of a clinical trial of a selective PDE4 inhibitor.
   Google Scholar
• HIGGS GA: The effects of CDP-840 on antigen induced airway responses in pre-clinical and clinical models of asthma. 212th ACS (1996):MEDI118.
   Google Scholar
• HAWKSWORTH R, HEATH P, LEE TH: The effects of single doses of CDP840, a potent and selective phosphodiesterase Type IV (PDE IV) inhibitor, on FEV1 in patients with bronchial asthma. Am. J. Resp. Crit. Care Med. (1996) 153:A347.
   Google Scholar
• MACLEOD D, O'TOOLE S, HEATH P, HOLGATE S: Evalua-tion of the safety and protection against histamine of a new sekective phosphodiesterase Type IV inhibitor, CDP840, in mild asthma. Am. J. Resp. Crit. Care Med. (1996) 153:A347.
   Google Scholar
• HARBINSON PL, SULLIVAN PJ, WAHID S et al: Effect of CDP-840, a selective inhibitor of phosphodiesterase Type IV (PDE IV) on the allergen induced asthmatic response. Am. J. Resp. Crit. Care Med. (1996) 153:A347.
   Google Scholar
• Piclamilast. Drugs Future. (1998) 23:918–919.
   Google Scholar
• •Useful review of RPR's compound.
   Google Scholar
• VACCARO SK, ARGENTI D, SHAH B, GILLEN MS, ROHATAGI S, JENSEN BK: Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodies-terase IV inhibitor (PDED. J. Clin. Pharmacol (1997) 37:Abstract 28.
   Google Scholar
• JONKER GJ, TIJHUIS GJ, DE MONCHY JGR: RP 73401 (a phosphodiesterase IV inhibitor) single dose does not prevent allergen induced broncho-constriction during the early phase reaction in asthmatics. Eur. Respir. J. (1996) 9(Suppl.):825.
   Google Scholar
• LANDELLS LJ, JENSEN MW, SPINA D et al.: Oral admini-stration of the phosphodiesterase (PDE) 4 inhibitor, V11294A inhibits ex-vivo agonist-induced cell activa-tion. Eur. Resp. J. (1998) 12\(Suppl. 28):362s.
   Google Scholar
• GALE DD, LANDELLS D, SPINA AJ et al.: Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDEO 4 inhibitor, V11294A, in human volunteers. ALA/ATS (1999) B123.
   Google Scholar
• Analysts meeting (1998)
   Google Scholar
• MACKAY IS: Classification and differential diagnosis of rhinitis. Eur. Respir. Rev. (1994) 4:245–247.
   Google Scholar
• •Useful review.
   Google Scholar
• NACLERIO RM: Pathophysiology of perennial allergic rhinitis. Allergy (1997) 52 (Suppl. 36):7–13.
   Google Scholar
• •Useful review.
   Google Scholar
• GOMEZ E, CORRADO OJ, BALDWIN DL, SWANTON AR, DAVIES RJ: Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in man. J. Allergy Clin. Immunol (1986) 78:673–545.
   Google Scholar
• NACLERIO RM, PROUD D, TOGIAS AG et al.: Inflamma-tory mediators in late antigen-induced rhinitis. New Engl. J. Med. (1985) 313:65–70.
   PubMed Web of Science ®Google Scholar
• •Useful review.
   Google Scholar
• LIM MC, TAYLOR RM, NACLERIO RM: The histology of allergic rhinitis and its comparision to cellular changes in nasal lavage. Am. J. Respir. Crit. Care Med. (1995) 151:136–144.
   PubMed Web of Science ®Google Scholar
• MOHAMMED S, YOPUNG A: Clinical aspects and treatment of chronic obstructive pulmonary disease. Curr. Opin. Anti-inflamm. Immunomodulatoiy Invest. Drugs (1999) 1:21–28.
   Google Scholar
• ••Very useful review.
   Google Scholar
• PRIDE NB, BURROWS B: Development of impaired lung function: natural history and risk factors. Chronic Obstructive Pulmonary Disease Calverly P, Pride N (Eds) Chapman & Hall Medical, London (1995):47–67.
   Google Scholar
• SANDFORD AJ, WEIR TD, PARE PD: Genetic risk factors for chronic obstructive pulmonary disease. Eur. Respir. J. (1997) 10:1380–1391.
   PubMed Web of Science ®Google Scholar
• CELLI BR, NIDER GL, HEFFNER J et al.: Standards for the diagnosis and care of patients with chronic obstruc-tive pulmonary disease. Am. J. Repir. Crit. Care Med. (1995) 152:S77–5120.
   PubMed Web of Science ®Google Scholar
• MURRAY CJL, LOPEZ A: Evidence-based health policy-lessons from the global burden of disease study. Science (1996) 274:740–743.
   PubMed Web of Science ®Google Scholar
• ANTHONISEN NR, CONNETT JE, KILEY JP et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J. Am. Med. Assoc. (1994) 272:1497–1505.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: Chronic obstructive pulmonary disease: new opportuniries for drug development. TiPS (1998) 19:415–423.
   PubMed Web of Science ®Google Scholar
• ••An informative review about existing and new treatments.
   Google Scholar
• CULPITT S, MAZIAK W, LOUKIDIS S, KELLER A, BARNES PJ: Effect of theophylline on induced sputum inflam-matory indices in COPD patients. Am. J. Respir. Crit. Care Med. (1998) 157:A797.
   Google Scholar
• WRIGHT CD, KUIPERS PJ, KOBYLARZ SINGER D, DEVALL LJ, KLINEFUS BA, WEISHAAR RE: Differential inhibition of human neutrophil functions: role of cyclic AMP-specific, cyclic GMP-insensitive phosphodies-terase. Biochem. Pharmacol. (1990) 40:699–707.
   PubMed Web of Science ®Google Scholar
• SCHUDT C, WINDERS, FORDERKUNZ S, HATZELMANN A, ULLRICH V: Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch. Pharmacol. (1991) 344:682–690.
   PubMed Web of Science ®Google Scholar
• TENOR H, HATZELMANN A, KUPFERCSHMIDT R et al.: Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy (1995) 25:625–633.
   PubMed Web of Science ®Google Scholar
• NIELSON CP, VESTAL RE, STURM RJ, HEASLIP R: Effect of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol (1990) 86:801–808.
   PubMed Web of Science ®Google Scholar
• BLOEMAN PGM, VAN DEN TWEEL MC, HENRICKS PAJ et al.: Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human broncial epithelial cells. Am. J. Pysiol. (1997) 272:L580–587.
   Google Scholar
• AL ESSA L, NIWA M, KOHNO K, NOZAKI M, TSURUMI K: Heterogeneity of circulating and exudated polymor-phonuclear leukocytes in superoxide-generating response to cyclic AMP and cyclic AMP-elevating agents: investigation of the underlying mechanism. Biochem. Pharmacol. (1995) 49:315–322.
   PubMed Web of Science ®Google Scholar
• OTTONELLO L, MORONE MP, DAPINO P, DALLEGRI F: Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating (GM-CSF) in adherent neutrophils. Clin. Exp. Immunol (1995) 101:502–506.
   PubMed Web of Science ®Google Scholar
• OTTONELLO L, MORONE MP, DAPINO P, DALLEGRI F: Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents. Br. J. Haematol (1995) 91:566–570.
   PubMed Web of Science ®Google Scholar
• BERENDS C, DIJKHUIZEN B, DEMONCHY JGR, DUBOIS AEJ, GERRITSEN J, KAUFFMAN HF: Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type-IV selective PDE inhibitor, rolipram. Eur. Respir. J. (1997) 10:1000–1007.
   PubMed Web of Science ®Google Scholar
• DERIAN CK, SANTULLI RJ, RAO PE, SOLOMAN HF, BARRETT JA: Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol (1995) 154:308–317.
   PubMed Web of Science ®Google Scholar
• SCHUDT C, TENOR H, HATZELMANN A: PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. 1 (1995) 8:1179–1183.
   PubMed Web of Science ®Google Scholar
• KAMBAYASHI T, JACOB CO, ZHOU D, MAZUREK N, FONG M, STRASSMANN G: Cyclic nucleotide phosphodiesterase Type IV participates in the regula-tion of IL-10 and the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J. Immunol (1995) 155:4909–4916.
   PubMed Web of Science ®Google Scholar
• KAMINUMA O, MURAKAMI S, SUKO M et al.: Late airway obstruction and neutrophil infiltration in sensitised mice after antigen provocation were suppressed by selective and non-selective phosphodiesterase inhibi-tors. All. Int. (1997) 46:101–108.
   Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al.: The second generation phosphodiesterase (PDE) 4 inhibitor, SB 207499, inhibits antigen-induced bronchoconstriction and eosinophilia and LPS-induced airway neutrophilia and edema in the guinea-pig. Eur. Respir. J. (1998) 12:86s.
   Google Scholar
• COMPTON CH, GUBB J, CEDAR E et al.: The efficacy of Ariflo (SB 207499), a second-generation, oral PDE4 inhibitor in patients with COPD. ALA/ATS (1999).
   Google Scholar
• BADGER AM, LEE JC: Advances in antiarthritic therapeutics. Drug Discov. Today (1997) 2:427–435.
   Web of Science ®Google Scholar
• ••An informative review about existing and new treatments.
   Google Scholar
• HARRIS ED, JR. : Rheumatoid arthritis. Pathophysi-ology and implications for therapy. New Engl. J. Med. (1990) 322:1277–1289.
   PubMed Web of Science ®Google Scholar
• GAY S, GAY RE, KOOPMAN WJ: Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction. Ann. Rheum. Dis. (1993) 52:S39–547.
   PubMed Web of Science ®Google Scholar
• BROOKES PM: Clinical management of rheumatoid arthritis. Lancet (1993) 341:286–290.
   PubMed Web of Science ®Google Scholar
• CONAGHAN PG, BROOKS P: Disease modifying anti-rheumatic drugs. Curr. Opin. Rheumatol. (1996) 8:176–182.
   PubMedGoogle Scholar
• PINCUS T : The paradox of effective therapies, but poor long term outcomes in rheumatoid arthritis. Arth. Rheum. (1992) 21:2–15.
   Web of Science ®Google Scholar
• MILLER LADNER U : Molecular and cellular interactions in the rheumatoid synovium. Curr. Opin. Rheumatol (1996) 8:210–220.
   PubMedGoogle Scholar
• FIRESTEIN GS, ZVAIFLER WJ : How important are T-cells in chronic rheumatoid synovitis? Arth. Rheum. (1990) 33:768–773.
   Google Scholar
• MAINI RN, ELLIOTT MJ, BRENNAN M, FELDMAN M: Beneficial effects of tumour necrosis factor-alpha (TNF-a) blockade in rheumatoid arthritis (RA). Clin. Exp. Immunol (1995) 101:207–212.
   PubMed Web of Science ®Google Scholar
• •An interesting paper on the biological approach to TNF blockade.
   Google Scholar
• PALFREYMAN MN, SOUNESS JE: Phosphodiesterase Type IV inhibitors. Prog. Med. Chem. (1996) 33:1–52.
   PubMedGoogle Scholar
• COHAN VL, SHOWELL HJ, FISHER DA et al.: In vitro pharmacology of the novel phosphodiesterase Type IV inhibitor, CP80-633. J. Pharm. Exp. Ther. (1996) 278:1356–1361.
   PubMed Web of Science ®Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al.: 5B207499 (Ariflo), a potent and selective second generation phosphodiesterase 4 inhibitor: in vitro antiinflammatory actions. J. Pharm. Exp. Ther. (1998) 284:420–426.
   PubMed Web of Science ®Google Scholar
• KAMBAYASHI T, JACOB W, ZHON D, MAZUREK N, FONG STRASSMAN G: Cyclic nucleotide phosphodiesterase Type 4 participates in the regulation of IL10 and the subsequent inhibition of TNF-a and IL6 release by endotoxin stimulated macrophages. J. Immunol. (1995) 155: 4909–4916.
   PubMed Web of Science ®Google Scholar
• LAPADULA G, IANNOS F, DELL'ACCIO F, COVELLI M, PIPITONE V: Interleukin 10 in rheumatoid arthritis. Clin. Exp. Rheumatol (1995) 13:629–632.
   PubMed Web of Science ®Google Scholar
• CHENG JB, WATSON JW, PAZOLES CJ et al.: The phosphodiesterase Type 4 (PDE4) inhibitor CP-80,633 elevates cyclic AMP levels and decreases TNFa produc-tion in mice: effect of adrenalectomy. J. Pharm. Exp. Ther. (1997) 280:621–626.
   PubMed Web of Science ®Google Scholar
• SINGH HN, BLANCUZZI V, GREENWOOD S, SKILES JW, O'BYRNE EM: Synovial fluid levels of tumour necrosis factor a in the inflamed rat knee: Modulation by dexamethasone and inhibitors of matrix metallopro-teinases and phosphodiesterases. Inflamm. Res. (1997) 46 (Suppl. 2):S153–S154.
   Google Scholar
• SEKUT L, YARNALL D, STIMPSON SA et al.: Antiinflamma-tory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin. Exp. Immunol. (1995) 100(1):126–132.
   PubMed Web of Science ®Google Scholar
• NYMAN U, MUSSENER A, LARSSON E, LORENTZEN J, KLARESKOG L: Amelioration of collagen II induced arthritis in rats by the Type IV phosphodiesterase inhibitor rolipram. Clin. Exp. ImmunoL (1997) 108:415–419.
   PubMed Web of Science ®Google Scholar
• ROSS S, WILLIAMS RO, MASON LJ et al.: Amelioration of established murine collagen-induced arthritis following treatment with rolipram. Br. J. Rheumatol. (1996) 35:Abstract Suppl. 1.
   Google Scholar
• SOUNESS JE, FOSTER M: Potential of phosphodiesterase Type IV inhibitors in the treatment of rheumatoid arthritis. Drugs (1998) 1(5):541–553.
   PubMedGoogle Scholar
• HULME C, METHEW R, MORIARTY K et al: Orally active indole-N-oxide PDE4 inhibitors. Bioorg. Med. Chem. Letts. (1998) 8(20:3053–3058.
   PubMedGoogle Scholar
• REGAN J, BRUNO J, McGARRY D et al: 2-Substituted-4-methoxy benzimidazole based PDE4 inhibitors. Bioorg. Merl. Chem. Letts. (1998) 8(19):2737–2742.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, JAWED S, PERROT S et al.: The clinical effects of RP73401 phosphodiesterase Type 4 inhibitor in patients with rheumatoid arthritis. Br. J. Rheumatol. (1997) 36:Abstr. Suppl. I, 186.
   Google Scholar
• CHIKANZA IC, JAWED SJ, BLAKE DR et al.: Treatment of patients with rheumatoid arthritis with RP73401 phosphodiesterase Type IV inhibitor. Arth. Rheum. (1996) 39(9):S282.
   Google Scholar
• MONTANA J, BIRD J: New therapeutic approaches to atopic dermatitis. Exp. Opin. Invest. Drugs. (1996) 5(9):1173–1180.
   Google Scholar
• •Provides a good overview of existing and potential therapies.
   Google Scholar
• HANIFIN JM, RAJKA G : Diagnostic features of atopic dermatitis. Acta Derm. Veneto]. (1980) 92:44–47.
   Google Scholar
• LEUNG DYM: Atopic Dermatitis: From Pathogenesis To Treatment. RG Landes Co. Austin, Texas, USA (1996):1–226.
   Google Scholar
• ••An informative review.
   Google Scholar
• BOGUNIEWICZ M: Advances in the understanding of atopic dermatitis. Curt. Opin. Pediatrics. (1997) 9(6):577–581.
   PubMedGoogle Scholar
• CROCKER IC, TOWNLEY RG, KHAN MM: Phosphodies-terase inhibitors suppress proliferation of peripheral blood mononuclear cells, and IL4 and IL5 secretion by human T-helper Type 2 cells. Immunopharmacology (1996) 31(2-3):223–235.
   PubMedGoogle Scholar
• LEUNG DYM, DIAZ LA, DeLE0 V, SOTER NA: Allergic and immunological skin disorders. JAMA (1997) 278 (22):1914–1923.
   PubMed Web of Science ®Google Scholar
• BOURNE HR, LICHTENSTEIN LM, HENNEY CS: Effects of cholera toxin on in vitro models of immediate and delayed type hypersensitivity: further evidence for the role of cAMP. j Clin. Invest. (1973) 52:691–697.
   PubMed Web of Science ®Google Scholar
• GANTNER F, GOTZ C, GEKENELER V, SCHUDT C, WENDEL A, HATZELMANN : Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibitors on B-cell proliferation. Br. J. Pharmacol. (1998) 123 (6):1031–1038.
   PubMed Web of Science ®Google Scholar
• BANNER KH, ROBERTS NM, PAGE CP: Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. B. J. Pharmacol. (1995) 116(8):3169–3174.
   PubMed Web of Science ®Google Scholar
• CHAN SC, HANIFIN JM: Differential inhibitory effects of cAMP phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med. (1993) 121 (1) : 44–51.
   PubMedGoogle Scholar
• •Provides insight into the potential differences between atopic and normal PDE4.
   Google Scholar
• MONTANA JG, COOPER N, DYKE HJ et al.: Phosphodies-terase 4 inhibitors: new xanthine analogues. Bioorg. Merl. Chem. Letts. (1998) 8:2925–2930.
   PubMed Web of Science ®Google Scholar
• MONTANA JG, BUCKLEY GM, COOPER N et al: Aryl sulphonamides as selective phosphodiesterase 4 inhibitors. Bioor. Merl. Chem. Letts. (1998) 8:2635–2640.
   PubMed Web of Science ®Google Scholar
• BEASLEY SC, COOPER N, GOWERS L et al.: Synthesis and evaluation of a novel series of phosphodiesterase 4 inhibitors. A potential treatment for asthma. Bioorg. Med. Chem. Letts. (1998) 8:2629–2634.
   PubMed Web of Science ®Google Scholar
• HANIFIN JM, CHAN SC, CHENG JB, HENDERSON Jr WR: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol (1996) 107:51–56.
   PubMed Web of Science ®Google Scholar
• NAGPAL S, CHANDRARATNA RAS: New dermatological agents for the treatment of psoriasis. Ann. Rep. Med. Chem. (1997) 32:201–210.
   Web of Science ®Google Scholar
• •An informative review about existing and new treatments.
   Google Scholar
• BAADSGAARD O: The role of the immune system in the pathogenesis of psoriasis. J. Invest. Dermatol (1990) 95:32S–34S.
   Google Scholar
• ANDERSON TF: Psoriasis. Med. Clin. North Am. (1982) 66 (4):769–794.
   PubMed Web of Science ®Google Scholar
• DUELL EA: Adenosine induced alterations in the adenosine 3'5'-monophosphate levels in mammalian epidermis. Mol. Pharmacol (1980) 18(0:49–52.
   PubMedGoogle Scholar
• RUSTIN LJ, DUELL EA, VOORHEES JJ: Papaverine and Ro20-1724 inhibit cyclic nucleotide phosphodies-terase activity and increase cAMP levels in psoriatic epidermis in vitro. J. Invest. Dermatol. (1978) 71(2):154–156.
   PubMed Web of Science ®Google Scholar
• KRAUSE W, KUHNE G: Anti-inflammatory activity of rolipram in a rat ear edema model. Arzneim-Forsch Drug Res. (1994) 44(1):163–165.
   PubMedGoogle Scholar
• STAWISKI MA, RUSTIN LJ, BURNS TL: Ro20-1724 An agent that significantly improves psoriatic lesions in double blind clinical trials. J. Invest. DermatoL (1979) 73 (4):261–263.
   PubMed Web of Science ®Google Scholar
• RAINE CS: The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann. Neurol (1994) 36:S61–72.
   Google Scholar
• LUCCHINETTI CF, BRUCK W, RODRIGUEZ M et al: Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. (1996) 6:259–274.
   PubMed Web of Science ®Google Scholar
• BRUCK W, BITSCH A, KOLENDA H et al.: Inflammatory central nervous system demylination; correlation of magnetic resonance imaging findings with lesion pathology. Ann. Neurol (1997) 42:783–93.
   PubMed Web of Science ®Google Scholar
• STORCH M, LASSERMAN H: Pathology and pathogenesis of demylinating disease. Curr. Opin. Neurol. (1997) 10:186–192.
   PubMedGoogle Scholar
• MILLER DH, GROSSMAN RI, REINGOLD SC et al.: The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain (1998) 121:3–24.
   PubMed Web of Science ®Google Scholar
• WEILBACH FX, GOLD R: Disease modifying treatments for multiple sclerosis. What is on the horizon? CNS Drugs (1999) 11:133–157.
   Web of Science ®Google Scholar
• •A useful review of new treatments.
   Google Scholar
• OZAWA K, SUCHANEK G, BREITSCHOPF H etal: Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 117:1311–1322.
   PubMed Web of Science ®Google Scholar
• TRAUGOTT U, RENHERZ EL, RAINE CS: Multiple sclerosis: distribution of T-cell subsets within active chronic lesions. Science (1984) 219:308–310.
   Web of Science ®Google Scholar
• CALDER V, OWEN S, WATSON C, FELDMAN M, DAVIDSON A: MS: a localised immune disease of the central nervous system. Immunol Today (1989) 10:99–103.
   PubMedGoogle Scholar
• FUJINAMI RS, OLDSTONE MB: Amino acid homology between the encephalitogenic site of mylin basic protein and virus: mechanism for autoimmunity. Science (1985) 230:1043–1045.
   PubMed Web of Science ®Google Scholar
• SELMAJ K, RAINE CS, CANELLA B, BROSNAN CF: Identifi-cation of lymphotoxin and tumour necrosis factor in multiple sclerosis lesions. J. Clin. Invest. (1991) 87:949–954.
   PubMed Web of Science ®Google Scholar
• WOODROOFE MN, CUZNER ML: Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridisa-tion. Cytokine (1993) 5:583–588.
   PubMed Web of Science ®Google Scholar
• SELMAJ KW, RAINE CS: Tumor necrosis factor mediates mylin and oligodendrocyte damage in vitro. Ann. Neurol (1988) 23:339–346.
   PubMed Web of Science ®Google Scholar
• HURWITZ AA, LYMAN WD, GUIDA MP, CALDERON TM, BERMAN JW: Tumor necrosis factor a induces adhesion molecule expression on human fetal astrocytes. J. Exp. Med. (1992) 176:1631–1636.
   PubMed Web of Science ®Google Scholar
• SHARIEF MK, THOMPSON EJ: In vivo relationship of tumor necrosis factor-a to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroim-munol (1992) 38:27–34.
   PubMed Web of Science ®Google Scholar
• RUDDLE NH, BERGMAN CM, MCGRATH KM et al: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalo-myelitis. J. Exp. Med. (1990) 172:1193–1200.
   PubMed Web of Science ®Google Scholar
• SELMAJ K, RAINE CS, CROSS AH: Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol (1991) 30:694–700.
   PubMed Web of Science ®Google Scholar
• SELMAJ K, PAPIERZ W, GLABINSKI A, KOHNO T: Preven-tion of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis Factor I. Neuroimmunol (1995) 56:135–141.
   PubMed Web of Science ®Google Scholar
• REENO T, KRAKOWSKI M, PICCIRILLO C et al.: TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis: regulation by Thl cytokines. J. Immunol. (1995) 154:944–953.
   PubMed Web of Science ®Google Scholar
• PROBERT L, AKASSOGLOU K, PASPARAKIS M et al.: Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-spewcific expression of tumor necrosis factor alpha. Proc. Natl. Acad. Sci. USA (1995) 92:11294–11298.
   PubMed Web of Science ®Google Scholar
• LIU J, MARINO MW, WONG G et al: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med. (1998) 4:78–83.
   PubMed Web of Science ®Google Scholar
• DINTER H, ONUFFER J, FAULDS D, PEREZ HD: Phosphodiesterase Type IV inhibitors in the treatment of multiple sclerosis. J. Mol. Merl. (1997) 75:95–102.
   PubMed Web of Science ®Google Scholar
• •A short review on the potential of PDE4 inhibitors in MS.
   Google Scholar
• SOMMER N, LOSCHMANN P-A, NORTHOFF GH et al.: The antidepressant rolipram suppresses cytokine produc-tion and prevents autoimmune encephalomyelitis. Nature Med. (1995) 1:244–248.
   PubMed Web of Science ®Google Scholar
• JUNG S, ZIELASEK J, KOLLNER G et al. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. (1996) 68:1–11..
   PubMed Web of Science ®Google Scholar
• GENAIN CP, ROBERTS T, DAVIS RL et al.: Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA (1995) 92:3601–3605.
   PubMed Web of Science ®Google Scholar
• SOMMER N, MARTIN R, MCFARLAND HF et al.: Therapeutic potential of phosphodiesterase Type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. (1997) 79:54–61.
   PubMed Web of Science ®Google Scholar
• •A short review on the potential of PDE4 inhibitors in MS.
   Google Scholar
• Scrip. (1997) 2228:10.
   Google Scholar
• COMPANY COMMUNICATION (1999).
   Google Scholar
• BICKSTON SJ, CAMINELLI F: Recent developments in the medical therapy of IBD. Curr. Opin. Gastroenterol (1998) 14:6–10.
   Web of Science ®Google Scholar
• ••Provides a good overview of this therapeutic area.
   Google Scholar
• MURTHY S, FLANIGAN A, OSBOURNE BJ, MURTHY NS: Inflammatory bowel disease: A new wave of therapy. Exp. Opin. Ther. Patents. (1998) 8(7):785–818.
   Web of Science ®Google Scholar
• ••Provides a good overview of this therapeutic area.
   Google Scholar
• SHIVANANDA S, LENNARD-JONES J, LOGAN RFA: Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Gut (1996) 39:690–697.
   PubMed Web of Science ®Google Scholar
• HANAVER SB: Aminosalicylate therapy for IBD. In: Inflammatory Bowel Diseases Rachmilewitz D (Ed), Kulwer Academic Press (1994):192–197.
   Google Scholar
• LOFBERG R: New steroids for inflammatory bowel disease. Inflamm. Bowel Dis. (1995) 1:135–141.
   PubMedGoogle Scholar
• ROSENBERG JL, LEVIN B, WALL AJ: A controlled trial of azathioprine in Crohns disease. Am. J. Dig. Dis. (1975) 20:721–726.
   PubMedGoogle Scholar
• PRESENT DH, MELTZER SJ, KRUMHOLTZ MP: 6-Mercaptopurine in the management of inflammatory bowel disease: short and long term toxicology. Ann. Intern. Med. (1989) 111:641–649.
   PubMed Web of Science ®Google Scholar
• FEAGAN BG, ROCHON J, FEDORAK RN: Methotrexate for the treatment of Crohns disease. New Engl. J. Med. (1995) 332:292–297.
   PubMed Web of Science ®Google Scholar
• RADFORD-SMITH G, JEWELL DP: Cytokines and inflam-matory bowel disease. Baillieres Clin. Gasteroenterol. (1996) 10:151–164.
   PubMedGoogle Scholar
• BRAEGGER CP, NICHOLLS S, MURCH SH: Tumour necrosis factor in the stool as a marker of intestinal inflammation. Lancet (1992) 339:89–91.
   PubMed Web of Science ®Google Scholar
• PUIG J, SALCEDO C, SALAS A, FERNANDEZ AG, PALACICOS JM: Curative effects of phoshodiesterase 4 inhibitors in dextran sulphate. Sodium induced colitis in the rat. Gastroententology (1998) 114(4): A1064.
   Google Scholar
• CARDELUS I, GRAS J, JAUREGUI J, LLENAS J, PALACIOS JM: Inhibiting LPS induced bowel erythrocyte extravasa-tion in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibitors. Eur. J. Pharmacol. (1996) 299:153–159.
   PubMed Web of Science ®Google Scholar
• CARDELUS I, GRAS J, PUIG J, LLENAS J, PALACIOS J M: Protective effects of denbufylline against endotoxin induced bowel hyperplasia. Met. Find. Exp. Clin. Pharamcol. (1995) 17 (Suppl. A):142
   Google Scholar
• DICKIE BGM, GREENFIELF SA: Chronic exposure to Ro20-1724 protects dopaminergic neurons in vitro against the neurotoxic action of N-methyl-D-aspartate and 1-methyl-4-phenylpyridinium. Brain Res. (1997) 753:335–339.
   PubMed Web of Science ®Google Scholar
• HULLEY P, HARTIKKA J, ABDEL'AL S et al.: Inhibitors of Type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. Eur. J. Neurosci. (1995) 7:2431–2440.
   Google Scholar
• EGAWA T, MISHIMA K, MATSUMOTO Y, IWASAKI K, IWASAKI K, FUJIWARA M: Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn. J. Pharmacol (1997) 75:275–281.
   PubMedGoogle Scholar
• IMANISHI T, SAWA A, ICHIMARU Y et al.: Ameliorating effects of rolipram on experimentally induced impair-ments of learning and memory in rodents. Eur. J. Pharmacol (1997) 321:273–278.
   PubMed Web of Science ®Google Scholar
• BARAD M, BOURTCHOULADZE R, WINDER DG, GOLAN H, KANDEL E: Rolipram, a Type IV-specific phosphodiesterase inhibitor, facilitates the establish-ment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. USA (1998) 95:15020–15025.
   PubMed Web of Science ®Google Scholar
• YAMASHITA N, MIYASHIRO M, BABA J, SAWA A et al.: Rolipram, a selective inhibitor of phosphodiesterase Type 4, pronouncedly enhanced the forskolin-induced promotion of dopamine biosynthesis in primary cultured rat mesencephalic neurons. Jpn. J. Pharmacol (1997) 75:91–95.
   PubMedGoogle Scholar
• BARNARD JW, SEIBERT AF, PRASAD VR et al.: Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. J. Appl. Physic)]. (1994) 77:774–781.
   PubMed Web of Science ®Google Scholar
• KATO H, ARAKI T, ITOYAMA Y, KOGURE K: Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil. Eur. j Pharmacol (1995) 272:107–110.
   PubMed Web of Science ®Google Scholar
• BLOCK F, TONDAR A, SCHMIDT W, SCHWARZ M: Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats. NeuroReport (1997) 8:3829–3832.
   PubMed Web of Science ®Google Scholar
• BELAYEV L, BUSTO R, IKEDA M et al.: Protection against blood-brain barrier disruption in focal cerebral ischemia by the Type IV phosphodiesterase inhibitor BBB022: a quantitative study. Brain Res. (1998) 787:277–285.
   PubMed Web of Science ®Google Scholar
• BEGANY DP, CARCILLO JA, HERZER WA, MI Z, JACKSON EK: Inhibition of Type IV phosphodiesterase by Ro-20-1724 attenuates endotoxin-induced acute renal failure. J. Pharmacol. Exp. Ther. (1996) 278:37–41.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO K, WAKI Y, HORITA T, KASUGAI S, OHYA K: Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem. Pharmacol. (1997) 54:613–617.
   PubMed Web of Science ®Google Scholar
• WAKI Y, HORITA T, MIYAMOTO K, OHYA K, KASUGAI S: Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapautic effects in rat osteopenia models. Jpn. Pharmacol (1999) 79:477–483.
   PubMedGoogle Scholar
• CARDELUS I, GRAS J, JAUREGI J, LLENAS J, PALACIOS JM: Inhibition of lipopolysaccharide-induced bowel erythrocyte extravasation in rats, and of mesenteric hypoperfusion in dogs, by phosphodiesterase inhibi-tors. Eur. J. Pharmacol (1996) 299:153–159.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, GRISTWOOD RW, COOPER N: Phosphodi-esterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? TIPS (1997) 18:164–171.
   PubMed Web of Science ®Google Scholar
• DOUSA MK, MOORE SB, PLOEGER NA, DEGOEY SR, DOUSA TP: Antagonists of cyclic nucleotide phosphodi-esterase (PDE) isozymes PDE3 and PDE4 suppress lymphoblastic response to HLA class II alloantigens: a potential novel approach to preventing allograft rejection? Clin. Neph. (1997) 47:187–189.
   Google Scholar
• LIANG L, BESHAY E, PRUD'HOMME GJ: The phosphodies-terase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes (1998) 47:570–575.
   PubMed Web of Science ®Google Scholar
• XIANG M, ZACCONE P, DI MARCO R et al.: Prevention by rolipram of concanavalin A-induced T-cell-dependent hepatitis in mice. Eur.J. Pharmacol. (1999) 367:399–404.
   Google Scholar
• XU H, STRASSMAN G, CHAN CC et al.: Protective effect of the Type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of the IL-lb-inducing activity. Invest. Ophthalmol. Visual Sci. (1999) 40:942–950.
   PubMed Web of Science ®Google Scholar
• KIM DH, LERNER A: Type 4 cyclic adenosine monophos-phate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood (1998) 92:2484–2494.
   PubMed Web of Science ®Google Scholar
• ANGEL JB, SAGET BM, WALSH SP et al.: Rolipram, a specific Type IV phosphodiesterase inhibitor, is a potent inhibitor of 111V-1 replication. AIDS (1995) 9:1137–1144.
   PubMed Web of Science ®Google Scholar
• NAVARRO J, PUNZON C, JIMENEZ JL et al.: Inhibition of phosphodiesterase Type IV suppresses human immunodeficiency virus Type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J. Virol. (1998) 72:4712–4720
   PubMed Web of Science ®Google Scholar